Cargando…

Controversies in the treatment of RAS wild-type metastatic colorectal cancer

OBJECTIVE: To provide guidance for the management of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in daily practice. METHODS: Nominal group and Delphi techniques were used. A steering committee of seven experts analyzed the current management of RAS wt mCRC, through which they identified c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vera, R., Salgado, M., Safont, M. J., Gallego, J., González, E., Élez, E., Aranda, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979622/ https://www.ncbi.nlm.nih.gov/pubmed/32789773 http://dx.doi.org/10.1007/s12094-020-02475-8

Ejemplares similares

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
por: Valladares-Ayerbes, Manuel, et al.
Publicado: (2022)

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
por: Elez, Elena, et al.
Publicado: (2019)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
por: Battaglin, Francesca, et al.
Publicado: (2019)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
por: Grasselli, J, et al.
Publicado: (2017)

Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
por: Lièvre, Astrid, et al.
Publicado: (2017)

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials
por: Benavides, Manuel, et al.
Publicado: (2019)

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
por: Lièvre, Astrid, et al.
Publicado: (2018)

Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
por: Yang, Jing, et al.
Publicado: (2017)

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era
por: Giordano, Guido, et al.
Publicado: (2021)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
por: Liao, Michael Z., et al.
Publicado: (2021)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
por: Sastre, J., et al.
Publicado: (2021)

Optimal Sequence and Second-Line Systemic Treatment of Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Meta-Analysis
por: Wu, Chih-Chien, et al.
Publicado: (2021)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
por: Tao, Huimin, et al.
Publicado: (2022)

Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014
por: Junior, Gilberto de Lima Lopes
Publicado: (2014)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
por: Fernández Montes, Ana, et al.
Publicado: (2023)

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
por: Gómez-España, M. A., et al.
Publicado: (2018)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2018)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
por: Köhne, Claus-Henning, et al.
Publicado: (2019)

Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with RAS Wild-Type Left-Sided Tumours in Canada
por: Boyne, Devon J., et al.
Publicado: (2023)

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
por: Taieb, Julien, et al.
Publicado: (2017)

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc
por: Yu, Yiyi, et al.
Publicado: (2016)

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
por: Toledo, Rodrigo A., et al.
Publicado: (2016)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens
por: Arikan, Rukiye, et al.
Publicado: (2023)

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2023)

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
por: Zekri, Jamal, et al.
Publicado: (2022)

RAS testing in metastatic colorectal cancer: advances in Europe
por: Van Krieken, J Han JM, et al.
Publicado: (2015)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
por: Kim, Sang-A, et al.
Publicado: (2021)

Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases
por: Harada, Kazuaki, et al.
Publicado: (2023)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
por: van Helden, Erik J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pmbo6i895r9si7sr5gop3dsdso